三元生物(301206) - 2022 Q1 - 季度财报

Revenue and Profitability - The company's revenue for Q1 2022 was ¥272,598,107.02, representing a 3.46% increase compared to ¥263,493,075.06 in the same period last year[3] - Net profit attributable to shareholders decreased by 9.64% to ¥62,765,994.16 from ¥69,465,064.33 year-on-year[3] - The net profit after deducting non-recurring gains and losses fell by 28.25% to ¥49,823,107.30 compared to ¥69,435,706.54 in the previous year[3] - Total operating revenue for Q1 2022 was CNY 272,598,107.02, an increase of 3.9% compared to CNY 263,493,075.06 in Q1 2021[19] - Net profit for Q1 2022 was CNY 62,765,994.16, a decrease of 9.7% from CNY 69,465,064.33 in Q1 2021[20] - Basic and diluted earnings per share for Q1 2022 were CNY 0.51, down from CNY 0.69 in Q1 2021[21] Cash Flow and Liquidity - The net cash flow from operating activities decreased significantly by 84.24% to ¥20,443,976.73 from ¥129,686,530.82 year-on-year[3] - The net cash flow from operating activities for Q1 2022 was ¥20,443,976.73, a decrease of 84.25% compared to ¥129,686,530.82 in Q1 2021[24] - Total cash inflow from operating activities was ¥312,922,891.80, while cash outflow was ¥292,478,915.07, resulting in a net increase of ¥9,443,976.73[24] - The ending balance of cash and cash equivalents was ¥267,134,010.23, compared to ¥141,186,753.95 at the end of Q1 2021, marking an increase of 89.38%[25] - The company received tax refunds amounting to ¥26,459,620.09, an increase from ¥17,947,944.83 in the previous year[24] Assets and Liabilities - Total assets increased by 213.32% to ¥5,120,094,004.66 from ¥1,634,157,434.85 at the end of the previous year[3] - Total liabilities for Q1 2022 were CNY 465,185,884.07, down from CNY 588,828,870.18 in Q1 2021[17] - Owner's equity totaled CNY 4,654,908,120.59 in Q1 2022, a substantial increase from CNY 1,045,328,564.67 in the same period last year[17] - Deferred income tax liabilities increased to CNY 25,228,040.35 in Q1 2022 from CNY 23,025,951.67 in Q1 2021[17] Investment and Expenditures - The company reported a significant increase in investment income due to enhanced fund management after receiving proceeds from the public offering[6] - The company invested ¥3,435,489,780.51 in various projects during the quarter, indicating a significant commitment to growth and expansion[24] - The company established a wholly-owned subsidiary, Sanyuan Biological Engineering Research (Tianjin) Co., Ltd., with an investment of RMB 5 million to enhance R&D capabilities[13] Shareholder Information - The total number of common shareholders at the end of the reporting period is 21,906[10] - The largest shareholder, Nie Zaijian, holds 45.94% of shares, totaling 61,964,000 shares[10] - The company raised a total of RMB 3,685,705,300 from the public offering of 33,721,000 shares at RMB 109.3 per share, with a net amount of RMB 3,546,644,640 after deducting issuance costs[12] Operating Costs and Expenses - Total operating costs for Q1 2022 were CNY 215,835,919.52, up 17.5% from CNY 183,703,681.92 in the same period last year[19] - Research and development expenses for Q1 2022 were CNY 10,219,983.55, a decrease of 11.7% compared to CNY 11,579,638.16 in Q1 2021[20] - The company experienced a 90.99% increase in cash paid for purchasing goods and services, attributed to a shift in payment methods due to rising raw material prices[7] - The cash paid for purchasing goods and services was ¥266,221,244.95, which is a substantial increase from ¥139,392,617.05 in Q1 2021[24] Audit and Reliability - The report for Q1 2022 was not audited, which may affect the reliability of the financial data presented[26]